TTI-621
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TTI-621 |
| Trade Name | |
| Synonyms | SIRPalpha-Fc|TTI621|TTI 621|ontorpacept |
| Drug Descriptions |
TTI-621 (ontorpacept) is a fusion protein consisting of the CD47 binding domain of SIRPalpha linked to the IgG1 Fc domain, which potentially enhances phagocytosis of tumor cells and inhibits tumor growth (PMID: 27856600, PMID: 33451977). |
| DrugClasses | CD47 Antibody 31 Immune Checkpoint Inhibitor 150 |
| CAS Registry Number | 2131089-46-6 |
| NCIT ID | C125718 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Daratumumab + TTI-621 | Daratumumab TTI-621 | 0 | 1 |
| Doxorubicin + TTI-621 | Doxorubicin TTI-621 | 0 | 1 |
| Pembrolizumab + TTI-621 | Pembrolizumab TTI-621 | 0 | 1 |
| TTI-621 | TTI-621 | 0 | 2 |
CKB BOOST